The estimated Net Worth of Daniel L Kisner is at least 42.5 千$ dollars as of 13 June 2023. Daniel Kisner owns over 115 units of Conatus Pharmaceuticals stock worth over 42,436$ and over the last 14 years he sold CNAT stock worth over 81$. In addition, he makes 0$ as Independent Director at Conatus Pharmaceuticals.
Sign up
Daniel Kisner CNAT stock SEC Form 4 insiders trading
Daniel has made over 7 trades of the Conatus Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 115 units of CNAT stock worth 40$ on 13 June 2023.
The largest trade he's ever made was buying 10,000 units of Conatus Pharmaceuticals stock on 21 July 2020 worth over 23,800$. On average, Daniel trades about 691 units every 87 days since 2010. As of 13 June 2023 he still owns at least 75,778 units of Conatus Pharmaceuticals stock.
You can see the complete history of Daniel Kisner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Kisner biography
Dr. Daniel L. Kisner M.D. serves as Independent Director of the Company. He currently serves as an independent consultant in the life science industry. He was a partner at Aberdare Ventures from 2003 to 2011. Dr. Kisner served as Chairman of the Board of Directors of Caliper Life Sciences from 2002 to 2008, and as President and CEO of its predecessor company, Caliper Technologies, from 1999 to 2002. He held positions of increasing responsibility at Isis Pharmaceuticals, Inc., from 1991 to 1999, most recently as President and COO. Dr. Kisner previously served in pharmaceutical research and development executive positions at Abbott Laboratories from 1988 to 1991 and at SmithKline Beckman Laboratories from 1985 to 1988. He held a tenured faculty position in the Division of Medical Oncology at the University of Texas, San Antonio School of Medicine until 1985 after a five-year advancement through the Cancer Treatment Evaluation Program of the National Cancer Institute. Dr. Kisner is board certified in internal medicine and medical oncology. Dr. Kisner holds a B.A. from Rutgers University and an M.D. from Georgetown University. Dr. Kisner currently serves as a director at Zynerba Pharmaceuticals and Dynavax Technologies Corporation, and has extensive prior private and public company board experience, including serving as Chairman of the Board of Directors at Tekmira Pharmaceuticals. Kisner is qualified to serve on our board of directors because of his extensive leadership experience in the biotechnology and biopharmaceutical industries and as a venture capital investor.
How old is Daniel Kisner?
Daniel Kisner is 73, he's been the Independent Director of Conatus Pharmaceuticals since 2014. There are no older and 6 younger executives at Conatus Pharmaceuticals.
What's Daniel Kisner's mailing address?
Daniel's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.
Insiders trading at Conatus Pharmaceuticals
Over the last 11 years, insiders at Conatus Pharmaceuticals have traded over 0$ worth of Conatus Pharmaceuticals stock and bought 1,570,135 units worth 17,229,485$ . The most active insiders traders include Shahzad Malik、Paul H Klingenstein、Preston Klassen. On average, Conatus Pharmaceuticals executives and independent directors trade stock every 83 days with the average trade being worth of 47,160$. The most recent stock trade was executed by Steven J Mento on 4 May 2018, trading 60,000 units of CNAT stock currently worth 59,400$.
What does Conatus Pharmaceuticals do?
Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.
What does Conatus Pharmaceuticals's logo look like?
Complete history of Daniel Kisner stock trades at Conatus Pharmaceuticals、Dynavax Technologies、Zynerba Pharmaceuticals Inc、Oncternal Therapeutics
Conatus Pharmaceuticals executives and stock owners
Conatus Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Steven Mento,
Director -
Daniel Kisner,
Independent Director -
Hayden Yizhuo Zhang,
Director -
Brian Satz,
Director -
Jonathan Jackson,
Director -
Stephen Chang,
Director -
Thomas Hubka,
Director of Business Operations, Corporate Secretary -
Martin Latterich,
Vice President - Technical Operations -
Edward Smith,
Senior Vice President - Regulatory Affairs and Quality Assurance -
Daniel Ripley,
Senior Vice President - Business Development, Program and Alliance Management -
Moya Daniels,
Executive Vice President and Head of Regulatory, Quality and Clinical Operations -
Susan Knudson,
Chief Financial Officer, Executive Vice President -
Gail Naughton,
Founder, Chief Scientific Officer, Chief Business Officer -
Richard Pascoe,
President, Chief Executive Officer, Director -
David Crean,
Chairman of the Board -
William R Larue,
Director -
Charles Cashion,
SVP, Finance, CFO and Sec. -
Shahzad Malik,
Director -
Alfred P. Spada,
EVP, R&D and CSO -
David T Hagerty,
EVP, Clinical Development -
Wart Harold Van,
Director -
James Paul Scopa,
Director -
Preston Klassen,
Director -
David F Hale,
Director -
Louis P Lacasse,
Director -
Kathleen D. Scott,
Director -
Keith W Marshall,
EVP, COO & CFO -
Michelle L Vandertie,
Vice President, Finance -
Venture Partners Llp Advent,
10% owner -
Luke Foley Todd Gadicke Ans...,
-
Bio Ventures Iv Qp Lpmpm Bi...,
-
Gp Iii, L.L.C.Aberdare Vent...,
-
Paul H Klingenstein,
Director -
Marc Olivier Perret,
Director -
Gilde Healthcare Ii U.A. Co...,
10% owner -
Gary C. Burgess,
Sr. VP, Clin. Res. & CMO